• Explore /
  • Poster
  • / A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.

A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.

Abstract Poster

Authors

null

Masafumi Ikeda

National Cancer Center Hospital East, Chiba, Japan

Masafumi Ikeda , Makoto Ueno , Chigusa Morizane , Satoshi Kobayashi , Izumi Ohno , Shunsuke Kondo , Naohiro Okano , Keisuke Kimura , Suguru Asada , Yoshinobu Namba , Takuji Okusaka , Junji Furuse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

JapicCTI-153098

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 306)

DOI

10.1200/JCO.2019.37.4_suppl.306

Abstract #

306

Poster Bd #

G4

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

First Author: Masayuki Furukawa

First Author: Nikhil I. Khushalani

First Author: Gerard Zalcman

First Author: Li Jingjing